![]() | |
Clinical data | |
---|---|
Trade names | Clozaprexin |
Other names | Docosahexaenoyl clozapine |
ATC code |
|
Legal status | |
Legal status | |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C40H49ClN4O |
Molar mass | 637.31 g·mol−1 |
3D model (JSmol) | |
| |
| |
![]() ![]() |
DHA-clozapine (tentative trade name Clozaprexin)[1] is an atypical antipsychotic drug candidate that was created and originally tested by chemists at Protarga, a small pharmaceutical in Pennsylvania, and scientists at Harvard University.[2]
It is a prodrug of clozapine; the fatty acid docosahexaenoic acid (DHA) was added to clozapine in order to increase penetration of the blood–brain barrier.[3]
Protarga was purchased by Luitpold Pharmaceuticals in 2003 and development was discontinued in 2007.[1]
© MMXXIII Rich X Search. We shall prevail. All rights reserved. Rich X Search